Abstract
Pruritus (itch) is a major symptom of several dermatological diseases but has limited therapeutic options available. Itch stimuli are transmitted via primary sensory neurons in the skin by activating pruriceptors/nociceptors on small unmyelinated C-fibers, through the spinal cord for final processing in the brain. CLE-400 is an aqueous gel of detomidine that is being developed for the topical treatment of itch. Detomidine is a potent α2-adrenergic receptor (α2-AR) agonist. α2-AR have been shown to be expressed on skin nociceptors and their activation by topical administration of detomidine could lead to inhibition of itch neural signalling.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
